Alpha 2.0
Login Register
» Articles » PMID: 8086768

Hepatitis B Vaccination of Immunosuppressed Heart Transplant Recipients with the Vaccine Hepa Gene 3 Containing Pre-S1, Pre-S2, and S Gene Products

Overview
Journal Clin Investig
Specialty General Medicine
Date 1994 May 1
PMID 8086768
Citations 4
Authors
D Wagner
I Wagenbreth
H A Thoma
A E Hemmerling
J Flik
Affiliations
Soon will be listed here.
Abstract

The antibody response of immunosuppressed heart transplant recipients to vaccination with the hepatitis B (HB) virus vaccine Hepa Gene 3 (HG-3), containing HB virus pre-S1, pre-S2, and S gene products, was examined. Three heart transplant recipients who had been vaccinated preoperatively against HB responded well to the vaccination. Five of 38 patients (13.2%) vaccinated postoperatively before HG-3 vaccination with the second-generation vaccine Gen-H-B-Vax-D (37 without and 1 with detectable anti-HBs response) and 3 of 24 (12.5%) without previous HB vaccination developed protective anti-HBs titers (greater than 10 U/l) after immunization with the HG-3 vaccine. The low response rate (8/62, 12.9%) found for postoperatively vaccinated patients indicates that heart transplant recipients should be vaccinated against HB before immunosuppressive medication.

Citing Articles

Prophylactic vaccination against hepatitis B: achievements, challenges and perspectives.

Gerlich W Med Microbiol Immunol. 2014; 204(1):39-55.

PMID: 25523195 DOI: 10.1007/s00430-014-0373-y.

Vaccination against infection in patients with multiple sclerosis.

Loebermann M, Winkelmann A, Hartung H, Hengel H, Reisinger E, Zettl U Nat Rev Neurol. 2012; 8(3):143-51.

PMID: 22270022 DOI: 10.1038/nrneurol.2012.8.

[Vaccination and multiple sclerosis].

Lobermann M, Winkelmann A, Reisinger E, Zettl U Nervenarzt. 2009; 81(2):181-93.

PMID: 19838662 DOI: 10.1007/s00115-009-2865-3.

Cardiac Transplantation: Pre-transplant Infectious Diseases Evaluation and Post-transplant Prophylaxis.

Keay S Curr Infect Dis Rep. 2002; 4(4):285-292.

PMID: 12126604 DOI: 10.1007/s11908-002-0019-x.

References
1.
Polywka S, Gatermann S, von Wulffen H, Laufs R . [Evaluation of the efficacy of a recombinant hepatitis B vaccine]. Immun Infekt. 1988; 16(5):175-8. View
2.
Benhamou E, Courouce A, Jungers P, Laplanche A, Degos F, BRANGIER J . Hepatitis B vaccine: randomized trial of immunogenicity in hemodialysis patients. Clin Nephrol. 1984; 21(3):143-7. View
3.
Stevens C, Alter H, Taylor P, Zang E, Harley E, SZMUNESS W . Hepatitis B vaccine in patients receiving hemodialysis. Immunogenicity and efficacy. N Engl J Med. 1984; 311(8):496-501. DOI: 10.1056/NEJM198408233110803. View
4.
CROSNIER J, Jungers P, Courouce A, Laplanche A, Benhamou E, Degos F . Randomised placebo-controlled trial of hepatitis B surface antigen vaccine in french haemodialysis units: II, Haemodialysis patients. Lancet. 1981; 1(8224):797-800. DOI: 10.1016/s0140-6736(81)92679-9. View
5.
Wagner D, Wagenbreth I, Flik J . Failure of vaccination against hepatitis B with Gen H-B-Vax-D in immunosuppressed heart transplant recipients. Clin Investig. 1992; 70(7):585-7. DOI: 10.1007/BF00184798. View